Skip to main content
SpringerLink
Log in

Neonatal klebsiella pneumonia sepsis and imipenem/cilastatin

  • Original Article
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Efficacy and safety of imipenem/cilastatin in neonatalKlebsiella pneumonia sepsis was investigated in 45 infants compared to 39 control infants on conventional antibiotic regimen. Sensitivity to imipenem was 94% followed by cephoxitin (88%), quinolons (80%), and amikacin (52%) according to susceptibility results in the study group. Treatment duration of surviving infants was 16.5±4.6 and 20.3±6.4 days in the study and control groups respectively (p<0.05). Five infants (11%) vs 27 (69%) were unresponsive (septic deaths) to treatment in the study and control groups respectively (p<0.001). The cure rates were 73% and 28% respectively (p<0.001). Sequelae free discharge rates were 67% and 23% respectively (p<0.001). The most frequent adverse effects of imipenem/cilastatin wereCandida albicans superinfection (20%);Candida albicans colonisation (10%); impairment of liver and renal functions (19% and 10% respectively); seizures (5%); thrombocytosis (3%); thrombophlebitis (3%); urine discoloration (3%); andStapylococcus epidermidis colonisation (2%). Imipenem is considered a good alternative for neonatalKlebsiella pneumonia sepsis with these results, however, one must be aware of the increased risk ofCandida albicans superinfection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gotoff SP. Infections of the neonatal infant. In: Beharman RE, Kliegman RM, Arvin AM. eds.Textbook of Pediatrics. Philadelphia: W.B. Saunders Colmpany, 1996: 514–450.

    Google Scholar 

  2. Toltzis P, Blumer JL, Antibiotic resistant gram-negative bacteria in the critical care setting.Pediatr Clin North Am 1995; 42: 687–702.

    PubMed  CAS  Google Scholar 

  3. Arvas A, Perk Y, Gür E, Ilter Ö. 1989–1992 yillari arasinda Yenidogan Ünitesinde izlenen bekeklerde infeksiyon dagilimi. Proceedings of XXX.Turkish Pediatric and II. National neonatology Congress, June 14–18th, 1993, Istanbul: pp 37–9.

  4. Oygür N. Yenidogan Ünitesinde Nozokomiyal infeksiyonlarin yillara göre dagilimi. Proceedings of XXX.Turkish Pediatrics and II. National Neonatolgy Congress, June 14–18th, 1993, Istanbul: pp 33–34.

  5. Satar M, Atici A, Yilmaz M. Yenidogan Ünitesinde Hastane Infeksiyonlari. Proceedings of XXX.Turkish Pediatrics and II. National Neonatology Congress, June 14–18th, 1993, Istanbul: pp 40.42.

  6. Ertogan F, Arsan S. Nozokomiyal infeksiyonlar (1988–1992). Proceedings of XXX.Turkish Pediatrics and II. National Neonatology Congress, June 14–18th, 1993 Istanbul: pp 35–36.

  7. Kültürsay, N, Kütükcüler N, Tansug N, Kutlu O. Etiology, treatment and prognosis of early-onset and nosocomial septicemia in neonatal intensive care unit.Annals Med Scien 1995; 4: 1–7.

    Google Scholar 

  8. Kültürsay, N, Tansug N, Kütükçüler N, Tokbas A, Kutlu O. Ceftazidime treatment in severe neonatal infections.Annals Med Scien 1995; 4: 8–12.

    Google Scholar 

  9. Freij BJ, McCracken GH, Olsen KD, Threlkeld N. Pharmacokinetics of imipenem-cilastatin in neonates.Antimicrob Ag Chemother 1985; 27: 431–435.

    CAS  Google Scholar 

  10. Buckley MM, Brogden RN, Barradell LB, Goa KL. Imipenem-cilastatin. Drugs 1992; 44: 408–444.

    Article  PubMed  CAS  Google Scholar 

  11. Lorens XS, Mccracken GH. Clinical Pharmacology of antibacterial agents. In: Remington J.S., Keelin J.O. eds.Infectious Disease of the fetus and newborn infants. Philadelphia: W.B. Saunders Company, 1995: 1310–1331.

    Google Scholar 

  12. Nalin DR, Hart CB, Shih WJ, Aziz MA. Imipenem-cilastatin for pediatric infections in hospitalized patients.Scand J Infect Dis 1987; 19 (Suppl) 52: 56–64.

    Google Scholar 

  13. Star SE. Antibacterial therapy of bacterial sepsis in the newborn.J Pediatr 1985; 106: 1043–1043.

    Article  Google Scholar 

  14. Geddes A, Roylance PJ. Clinical experience with imipenem cilastatin: a 5 year overview.Curr Op Infect Dis 1991; 4 (suppl 1): 53–59.

    Google Scholar 

  15. Alpert G, Dagan R, Connor Eet al. Imipenem-cilstatin for the treatment of infections in hospitalised children.Am J Dis Child 1985; 139: 1153–1156.

    PubMed  CAS  Google Scholar 

  16. Nalin DR, Jacobson CA. Imipenemcilastatin therapy for serious infection in neonates and infants.Scand J Infect Dis 1987; 19 (suppl 52): 2–11.

    Google Scholar 

  17. Ahonkai VI, Cyhan GM, Wilson SE, Brown KR. Imipenem-cilastatin in pediatric patients: an overview of safety and efficacy in studies conducted in the United States.Pediat Infect Dis J 1989; 8: 740–744.

    Article  Google Scholar 

  18. Collins MA, Tyoypin M. Collaborative Imipenem-cilastatin study group. Clinical evaluation of Imipenem-cilastatin as a single agent therapy for sepsis neonatorum.27th Intersci Conf Antimicrob Chemother Agents 1987; Abstract, p. 525.

  19. Reisch O, Ashkenazi S, Naor N. An outbreak of multiresistant Klebsiella in a neonatal intensive care unit.J Hosp Infect 1993; 25: 287–289.

    Article  Google Scholar 

  20. Somer A, Salman N, Palanduz A, Guler N, Yalcin I, Ones U. Cocuklarda ciddi infeksiyonlarin tedavisinde Imipenem-cilastatin kullanimi.Proceedings of 10th Turkiye Antibiotics and Chemotherapy Congress, June 6–9th 1995, Antalya, p. 167.

  21. Mutlu G, Candan M, Pektas O, Bulut M. Cerrahi problemi olan yenidoganlanin ciddi infeksiyonlarinda Imipenemcilastatin kullanimi.Proceedings of 10th Turkiye Antibiotics and Chemotherapy Congress, June 6–9th 1995, Antalya, p 151.

  22. Favero AD. Clinically important aspects of carbapenem safety.Cur Op Infect Dis 1994; 7 (Suppl 1): 38–42.

    Google Scholar 

  23. Asensi F, Otero MC, Perez-Tamaritet al. Risk/benefit in the treatment of children with Imipenem-cilastatin for meningitis caused by penicillin resistant pneumococcus.J Chemother 1993; 5: 133–134.

    PubMed  CAS  Google Scholar 

  24. Ucsel R, Coban A, Karabiyik N, Metin F, Yucer G, Can G. Yenidogan infeksiyonlarinda Imipenem-cilastatin kullanimi ile ilgili deneyimlerimiz.Ist Tip Fak Mec 1995; 58: 37–40.

    Google Scholar 

  25. Gruber WC, Rench MA, Garcia-Pratz JA, Edwards MS, Baker CJ. Single-dose pharmacokinetics of Imipenem-cilastatin in neonates.Antimicr Agent Chemother 1985; 27: 511–514.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Ege University Medical Faculty, Bornova 35100, Izmir, Turkey

    Resmiye Oral, Mete Akisü & Fadil Vardar

  2. Department of Pediatrics, Division of Neonatology and Pediatric Infectious Diseases, Izmir, Turkey

    Nilgün Kültürsay & Nermin Tansuĝ

Authors
  1. Resmiye Oral
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mete Akisü
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nilgün Kültürsay
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fadil Vardar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nermin Tansuĝ
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mete Akisü.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oral, R., Akisü, M., Kültürsay, N. et al. Neonatal klebsiella pneumonia sepsis and imipenem/cilastatin. Indian J Pediatr 65, 121–129 (1998). https://doi.org/10.1007/BF02849703

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02849703

Key words

Search

Navigation